CNSP News and Press, CNS Pharmaceuticals Inc. From 11/22/23

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluat...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, has announced the presentation of updated safety data from its ongoing potentially pivotal study evaluat...

Data presented at the Society of NeuroOncology (SNO) 28 th Annual Meeting Berubicin currently being evaluated in an ongoing potentially pivotal study for the treatment of Glioblastoma Multiforme (GBM) Topline result from preplanned interim futility analysis on track for December 2023 ...

Medulloblastoma is a rare type of brain tumor that is primarily found in children. It is estimated that about 350 cases of this illness are diagnosed annually. This cancer often resists treatment, which involves a combination of radiation, surgery and chemotherapy. This, combined with the diseas...

2023-11-20 17:42:09 ET More on CNS Pharmaceuticals Seeking Alpha’s Quant Rating on CNS Pharmaceuticals Financial information for CNS Pharmaceuticals For further details see: CNS Pharmaceuticals files to sell 3.76M shares of common stock for holders

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, specifically aggressive brain cancers. The company today announced its confidence in sharing the results from an interim analysis on one of its lead ...

HOUSTON, TX / ACCESSWIRE / November 16, 2023 / Glioblastoma is a highly aggressive type of brain cancer with no cure, leading to a grim prognosis and average survival time of only 14 to 16 months . With no approved treatment for recurrent GBM anywhere in the world, it is considered one of the...

CNS Pharmaceuticals (NASDAQ: CNSP) , a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting on its financial results for third quarter, the period ended Sept. 30, 2023; the company al...

- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment in December 2023 - Topline data from preplanned interim analysis from ongoing Berubicin potentially pivotal study expected in December 2023 - Raised $2.6 milli...

A team of researchers from Nottingham Trent University and the University of Sheffield is developing a first-of-its-kind finger-prick test to test for brain cancer. The research team says the simple test could make it easier to spot recurring brain tumors and even extend the lives of tens of tho...